News - Vivus, Topamax

Filter

Current filters:

VivusTopamax

Popular Filters

1 to 25 of 40 results

Vivus earnings beat expectations

25-02-2014

USA-based Vivus has reported fourth-quarter and full-year 2013 financial results that beat analysts’…

FinancialPharmaceuticalVivus

Auxilium gains rights to Vivus ED drug for USA and Canada

11-10-2013

Auxilium Pharmaceuticals has signed an agreement with fellow USA-based Vivus providing Auxilium with…

Auxilium PharmaceuticalsLicensingMen's HealthNorth AmericaPharmaceuticalStendraVivus

Vivus obesity drug reduces progression to type 2 diabetes in high-risk overweight patients

10-10-2013

New data published on-line in Diabetes Care, today Care demonstrating positive effects of USA-based Vivus’…

DiabetesMetabolicsPharmaceuticalQsymiaResearchVivus

Market for obesity therapies to reach a value of $2.6 billion in 2019

16-09-2013

The global obesity therapeutics market has been forecast to increase at a compound annual growth rate…

GlobalMarkets & MarketingMetabolicsPharmaceuticalQsymiaVivus

Anti-obesity drug market to more than triple by 2019; report

05-09-2013

The anti-obesity drug market, which is dominated by off-patent orlistat, Swiss pharma major Roche's (ROG:…

Markets & MarketingMetabolicsorlistatPharmaceuticalQsymiaRocheVivusXenical

Resubmission expected for Orexigen's obesity drug Contrave

29-08-2013

US biopharma company Orexigen Therapeutics (Nasdaq: OREX) has announced that the Light Study independent…

Arena PharmaceuticalsBelviqContraveGastro-intestinalsNorth AmericaOrexigen TherapeuticsPharmaceuticalQnexaRegulationVivus

Sanofi to produce avanafil for Vivus

02-08-2013

US drugmaker Vivus (Nasdaq: VVUS) says it has entered into a commercial supply agreement with French…

avanafilMen's HealthPharmaceuticalProductionSanofiSpedraVivus

Vivus reaches agreement with First Manhattan and appoints new board

19-07-2013

A truce has been called between US drugmaker Vivus (Nasdaq: VVUS) and its top investor First Manhattan…

ManagementNorth AmericaPharmaceuticalVivus

Law suit threat for Vivus over battle for shareholders' votes

17-07-2013

The battle has heated up between US drugmaker Vivus (Nasdaq: VVUS) and its top investor First Manhattan…

FinancialNorth AmericaPharmaceuticalQsymiaVivus

Vivus offers a compromise to end the proxy contest

14-07-2013

US drugmaker Vivus (Nasdaq: VVUS) said on Saturday (July 13) that it had communicated to Sam Colin and…

ManagementPharmaceuticalQsymiaVivus

European approval for Vivus' ED drug Spedra

27-06-2013

The European Commission yesterday (June 26) has granted marketing authorization for USA-based Vivus'…

avanafilEuropeMen's HealthPharmaceuticalRegulationReproductiveSpedraVivus

It's official: "obesity is a disease," says AMA

20-06-2013

The American Medical Association at its annual meeting this week adopted a policy that recognizes obesity…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Vivus rises as FDA eases restrictions on diet pill Qsymia

17-04-2013

USA drugmaker Vivus' (Nasdaq: VVUS) shares rose as much as 11% by traded up 5% at $11.69, after the company…

MetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Vivus announces new discount program for obesity drug Qsymia

06-03-2013

US drugmaker Vivus (Nasdaq: VVUS) has announced a new program offering eligible patients a discount on…

Markets & MarketingMetabolicsNorth AmericaPharmaceuticalPricingQsymiaVivus

EMA confirms negative view on Vivus' obesity drug Qsiva after appeal

22-02-2013

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) dealt a blow to…

EuropeMetabolicsPharmaceuticalQsivaQsymiaRegulationVivus

Express Scripts adds Vivus' Qsymia to its standard benefits program

20-12-2012

US drugmaker Vivus (Nasdaq: VVUS) says that Express Scripts, among the USA's largest Pharmacy Benefit…

Express ScriptsMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaVivus

Vivus gets formal "No" from EMA panel on obesity drug

19-10-2012

US drugmaker Vivus (Nasdaq: VVUS) revealed yesterday that is has received the formal opinion from the…

EuropeMetabolicsPharmaceuticalQsivaRegulationVivus

Strong start for Vivus' obesity drug Qsymia; deal with Express Scripts

10-10-2012

Sales of US drugmaker Vivus' (Nasdaq: VVUS) obesity agent Qsymia (phentermine and topiramate extended-release)…

Express ScriptsMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaVivus

Vivus debuts weight-loss pill Qsymia on US market

19-09-2012

USA-based Vivus (Nasdaq: VVUS) saw its shares rise 3.9% to $22.93 on Monday, after the company announced…

Markets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaVivus

1 to 25 of 40 results

Company Spotlight

Fibrotech

Fibrotech

Back to top